LAMDA PHARMA LIMITED

Company number 09421468 ·

Active

This analysis was written by an AI from the company's public filings. It may contain errors or omissions and is not financial or professional advice.

Risk Rating: MEDIUM

Justification: LAMDA PHARMA LIMITED is an active private limited company with statutory filings currently up to date and no insolvency proceedings. However, it is classified as a non-trading company with nominal share capital of £1, and the available data contains no balance sheet, profit and loss, or cash flow figures. Its status as an audit exemption subsidiary, with a corporate person with significant control holding over 75% of voting rights, indicates dependence on a parent entity, but solvency and liquidity cannot be verified without financial statements.

Key Concerns

  1. No financial data provided: The company information includes no balance sheet, current assets, current liabilities, or cash position. With share capital of only £1, net assets and working capital are unknown, making it impossible to confirm whether the company can meet its obligations.

  2. Non-trading status: The SIC code (74990 Non-trading company) indicates the company undertakes no trading activity and generates no operating revenue. Its sustainability therefore depends on support from its parent, Quantum Pharma Group Limited, or on non-operating assets that are not disclosed.

  3. Recent board change: A director resigned on 5 October 2026. For a small company with a limited officer base, this change may affect governance continuity and decision-making capacity and should be verified.

Positive Indicators

  • The company is active and not in liquidation, administration, or receivership.
  • Accounts and confirmation statement filings are not overdue.
  • It forms part of a group structure (audit exemption subsidiary; corporate PSC with over 75% voting rights), which may imply access to group resources.
  • Incorporated in 2015, indicating an established corporate history.

Due Diligence Notes

  • Obtain the latest filed annual accounts to review fixed assets, current assets, current liabilities, net assets, and shareholders’ funds.
  • Identify any intercompany balances with Quantum Pharma Group Limited, including loans, guarantees, or amounts payable or receivable.
  • Confirm the reason for the recent director resignation and assess whether the remaining directors can maintain adequate governance.
  • Verify whether the company holds any material property, investments, or other assets despite its non-trading classification.
  • Review the group structure for any cross-guarantees, funding arrangements, or dependency provisions affecting the company’s obligations.

Perspective: Investment Risk Assessor · Model: nvidia/nemotron-3.5-super-vl:free · Generated 15 November 2026